Cutaneous melanoma of the head and neck: Advances in evaluation and treatment

Plastic and Reconstructive Surgery

Volumn 105, Issue 6, 2000, Pages 2105-2126

  Stadelmann, Wayne K ^a   McMasters, Kelly ^b   Digenis, Alexander G ^b   Reintgen, Douglas S ^b  

^a University of Louisville School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; LYMPH NODE DISSECTION; LYMPHOSCINTIGRAPHY; MELANOMA; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TUMOR BIOPSY;

EID: 0034099048     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006534-200005000-00031     Document Type: Article

References (132)

1. Barth, A., Wanek, L. A., and Morton, D. L. Prognostic factors in 1521 melanoma patients with distant metastases. J. Am. Coll. Surg. 181: 193, 1995.
2. Landis, S. H., Murray, T., Bolden, S., and Wingos, P. A. Cancer statistics, 1998. CA Cancer J. Clin. 48: 6, 1998.
3. Evans, G. R. D., and Manson, P. N. Review and current perspectives of cutaneous malignant melanoma. J. Am. Coll. Surg. 178: 523, 1994.
4. Davidsson, A., Hellquist, H. B., Villman, K., and Westman, G. Malignant melanoma of the ear. J. Laryngol. Otol. 107: 798, 1993.
5. Balch, C. M., Soong, S.-J., Bartolucci, A. A., et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann. Surg. 224: 255, 1996.
6. Balch, C. M., Cascinelli, N., Sim, F. H., Soong, S.-J., Taylor, W. F., and Bufalino, R. Elective Lymph Node Dissection: Results of Prospective Randomized Surgical Trials. In C. M. Balch (Ed.), Cutaneous Oncology, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 209-226.
7. Sim, F. H., Taylor, W. F., Ivins, J. C., et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: Preliminary results. Cancer 41: 948, 1978.
8. Veronesi, U., Adamus, J., Bandiera, D. C., et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N. Engl. J. Med. 297: 627, 1977.
9. American Joint Committee on Cancer. Manual for Staging of Cancer, 3rd Ed. Philadelphia: Lippincott, 1988. P. 139.
10. Perez, I. R., Fenske, N. A., and Brozena, S. I. Malignant melanoma: Differential diagnosis of the pigmented lesion. Semin. Surg. Oncol. 9: 168, 1993.
11. Carlson, J. A., Dickersin, G. R., Sober, A. J., and Barnhill, R. L. Desmoplastic neurotropic melanoma: A clinicopathologic analysis of 28 cases. Cancer 75: 478, 1995.
12. Gershenwald, J. E., Colome, M. I., Lee, J. E., et al. Patterns of recurrence following a negative sentinel node biopsy in 243 patients with stage I or II melanoma. J. Clin. Oncol. 16: 2253, 1998.
13. Breslow, A. Prognostic factors in the treatment of cutaneous melanoma. J. Cutan. Pathol. 6: 208, 1979.
14. Büttner, P., Garbe, C., Bertz, J., et al. Primary cutaneous melanoma, optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 75: 2499, 1995.
15. Carmichael, V., Davidson, V. V., and Wilson, K. S. Analysis of prognostic factors in clinical stage I cutaneous malignant melanoma (CMM): British Columbia Cancer Agency (BCCA) experience 1972-1981. Proc. ASCO 11: 1191, 1992.
16. Clark, W. H., Jr., Elder, D. E., Guerry, D., et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl. Cancer Inst. 81: 1893, 1989.
17. Drzewiecki, K. T., and Andersen, P. K. Survival with malignant melanoma: A regression analysis of prognostic factors. Cancer 49: 2414, 1982.
18. Garbe, C., Büttner, P., Bertz, J., et al. Primary cutaneous melanoma: Prognostic classification of anatomic location. Cancer 75: 2492, 1995.
19. Heaton, K. M., Sussman, J. J., Gersenwald, J. E., et al. Surgical margins and prognostic factors in patients with thick (> 4.0 mm) primary melanoma. Ann. Surg. Oncol. 5: 322, 1998.
20. Karakousis, C. P., Emrich, L. J., and Rao, U. Tumor thickness and prognosis in clinical stage I malignant melanoma. Cancer 64: 1432, 1989.
21. Meyskens, F. L., Jr., Berdeaux, D. H., Parks, B., Tong, T., Loescher, L., and Moon, T. E. Cutaneous malignant melanoma (Arizona Cancer Center experience). I. Natural history and prognostic factors influencing survival in patients with stage I disease. Cancer 62: 1207, 1988.
22. Reintgen, D. S., Cox, E., Vollmer, R., McCarty, K. S., and Seigler, H. F. Mathematical model to predict prognosis for stage I cutaneous melanoma. Surg. Forum 43: 211, 1983.
23. Schuchter, L., Schultz, D. J., Synnestvedt, M., et al. A prognostic model for predicting 10-year survival in patients with primary melanoma: The Pigmented Lesion Group. Ann. Intern. Med. 125: 369, 1996.
24. Schultz, S., Kane, M., Roush, R., et al. Time to recurrence varies inversely with thickness in clinical stage 1 cutaneous melanoma. Surg. Gynecol. Obstet. 171: 393, 1990.
25. Morton, D. L., Giuliano, A. E., Reintgen, D. S., Roses, D. F., Ross, M. I., and Thompson, J. F. Symposium: Lymphatic mapping and sentinel node biopsy in patients with breast cancer and melanoma, part 2. Contemp. Surg. 53: 353, 1998.
26. Wells, K. E., Rapaport, D. P., Cruse, C. W., et al. Sentinel lymph node biopsy in melanoma of the head and neck. Plast. Reconstr. Surg. 100: 591, 1997.
27. Giles, G., Staples, M., McCredic, M., and Coates, M. Multiple primary melanomas: An analysis of cancer registry data from Victoria and New South Wales. Melanoma Res. 5: 433, 1995.
28. Scheibner, A., Milton, G. W., McCarthy, W. H., Norlund, J. J., and Pearson, L. J. Multiple primary melanomas: A review of 90 cases. Australas. J. Dermatol. 23: 1, 1982.
29. Tucker, M. A., Eraser, M. C., Goldstein, A. M., et al. Risk of melanoma and other cancers in melanomaprone families. J. Invest. Dermatol. 100: 350s, 1993.
30. Wassberg, C., Thorn, M., Yuen, J., et al. Second primary cancers in patients with cutaneous malignant melanoma: A population-based study in Sweden. Br. J. Cancer 73: 255, 1996.
31. Epstein, D. S., Lange, J. R., Gruber, S. B., Mofid, M., and Koch, S. E. Is physician detection associated with thinner melanomas? J.A.M.A. 281: 640, 1999.
32. Marghoob, A. A., Slade, J., Salopek, T., et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma: Screening implications. Cancer 75 (2 Suppl): 707, 1995.
33. Eldh, J. Excisional biopsy and delayed wide excision versus primary wide excision of malignant melanoma. Scand. J. Plast. Reconstr. Surg. 13: 341, 1979.
34. Landthaler, M., Braun-Falco, O., Leitl, A., Konz, B., and Hoelzel, D. Excisional biopsy as the first therapeutic procedure versus primary wide excision of malignant melanoma. Cancer 64: 1612, 1989.
35. Lederman, J. S., and Sober, A. J. Does wide excision as the initial diagnostic procedure improve prognosis in patients with cutaneous melanoma? J. Dermatol. Surg. Oncol 12: 697, 1986.
36. Clark, W. H., Jr., and Mihm, M. C., Jr. Lentigo maligna and lentigo maligna melanoma. Am. J. Pathol. 55: 39, 1969.
37. Gaspar, Z. S., and Dawber, R. P. Treatment of lentigo maligna. Australas. J. Dermatol. 38: 1, 1997.
38. Mihm, M. C., Barnhill, R. L., Sober, A. J., and Hernandez, M. H. Precursor lesions of melanoma: Do they exist? Semin. Surg. Oncol. 8: 358, 1992.
39. Wayte, D. M., and Helwig, E. B. Melanotic freckle of Hutchinson. Cancer 21: 893, 1968.
40. Koh, H. K., Michalik, E., Sober, A. J., et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J. Clin. Oncol. 2: 994, 1984.
41. Stadelmann, W. K., and Reintgen, D. S. Prognosis in malignant melanoma. Hematol. Oncol. Clin. North Am. 12: 767, 1998.
42. Kelly, J. W. Following lentigo maligna may not prevent the development of life-threatening melanoma. Arch. Dermatol. 128: 657, 1992.
43. Cohen, L. M., McCall, M. W., and Zax, R. H. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma: A follow-up study. Dermatol. Surg. 24: 673, 1998.
44. Olhoffer, I. H., and Bolognia, J. L. What's new in the treatment of cutaneous melanoma. Semin. Cutan. Med. Surg. 17: 96, 1998.
45. Coleman, W. P., III, Davis, R. S., Reed, R. J., and Krementz, E. T. Treatment of lentigo maligna and lentigo maligna melanoma. J. Dermatol. Surg. Oncol. 6: 476, 1980.
46. Pitman, G. H., Kopf, A. W., Bart, R. S., and Casson, P. R. Treatment of lentigo maligna and lentigo maligna melanoma. J. Dermatol. Surg. Oncol. 5: 727, 1979.
47. Robinson, J. K. Margin control for lentigo maligna. J. Am. Acad. Dermatol. 31: 79, 1994.
48. Conley, J., Lattes, R., and Orr, W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 28: 914, 1971.
49. Reed, R. J., and Leonard, D. D. Neurotropic melanoma. Am. J. Surg. Pathol. 3: 301, 1979.
50. Beenken, S., Byers, R., Smith, L. J., Goepfort, H., and Shallenberger, R. Desmoplastic melanoma, histologic correlation with behavior and treatment. Arch. Otolaryngol. Head Neck Surg. 115: 374, 1989.
51. Smithers, B. M., Mcleod, G. R., and Little, J. H. Desmoplastic melanoma: Patterns of recurrence. World J. Surg. 16: 186, 1992.
52. Smithers, B. M., Mcleod, G. R., and Little, J. H. Desmoplastic, neural transforming and neurotropic melanoma: A review of 45 cases. Aust. N. Z. J. Surg. 60: 967, 1990.
53. Wong, J. H., Cagle, L. A., and Morton, D. L. Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch. Surg. 122: 1380, 1987.
54. Chang, P., and Knapper, W. H. Metastatic melanoma of unknown primary. Cancer 49: 1106, 1982.
55. Stadelmann, W. K., Rapaport, D. P., Soong, S. J., Reintgen, D. S., and Balch, C. M. Prognostic, Clinical, and Pathologic Features. In C. M. Balch (Ed.), Cutaneous Oncology, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 11-35.
56. Nasri, S., Namazie, A., Dulguerov, P., and Mickel, R. Malignant melanoma of cervical and parotid lymph nodes with an unknown primary site. Laryngoscope 104: 1194, 1994.
57. Buzaid, A. C., Sandler, A. B., Mani, S., et al. Role of computed tomography in the staging of primary melanoma. J. Clin. Oncol. 11: 638, 1993.
58. Karakousis, C. P. Therapeutic node dissections in malignant melanoma. Ann. Surg. Oncol. 5: 473, 1998.
59. Reintgen, D. S., Albertini, J., Miliotes, G., et al. The accurate staging and modern day treatment of malignant melanoma. Cancer Res. Ther. Control 4: 183, 1995.
60. Crowley, N. J., and Seigler, H. F. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer 66: 2522, 1990.
61. Reintgen, D., Rapaport, D. P., Tanabe, K. K., and Ross, M. Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma. J. Fla. Med. Assoc. 84: 188, 1997.
62. Coates, A. S., Ingvar, C. I., Petersen-Schaefer, K., et al. Elective lymph node dissection in patients with primary melanoma of the truck and limbs treated at the Sydney Melanoma Unit from 1960 to 1991. J. Am. Coll. Surg. 180: 402, 1995.
63. Berman, C. G., Norman, J., Cruse, C. W., Reintgen, D. S., and Clark, R. A. Lymphoscintigraphy in malignant melanoma. Ann. Plast. Surg. 28: 29, 1992.
64. Feind, C. R., and Cole, R. M. Contralateral spread of head and neck cancer. Am. J. Surg. 118: 660, 1969.
65. Norman, J., Cruse, C. W., Espinosa, C., et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am. J. Surg. 162: 432, 1991.
66. Wanebo, H. J., Harpole, D., and Teates, C. D. Radio-neucleolide lymphoscintigraphy with technetium 99m antimony sulfide colloid to identify lymphatic drainage of cutaneous melanoma at ambiguous sites in the head and neck and trunk. Cancer 55: 1403, 1985.
67. Wells, K. E., Cruse, C. W., Daniels, S., Berman, C., Norman, J., and Reintgen, D. The use of lymphoscintigraphy in melanoma of the head and neck. Plast. Reconstr. Surg. 93: 757, 1994.
68. Reintgen, D. S., Albertini, J., Berman, C., et al. Accurate nodal staging of malignant melanoma. Cancer Control J. Moffitt Cancer Center 2: 405, 1995.
69. Fisher, S. R., and O'Brien, C. J. Head and Neck Melanoma. In C. M. Balch (Ed.), Cutaneous Oncology, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 163-174.
70. Kelemen, P. R., Wanek, L. A., and Morton, D. L. Lymph node biopsy does not impair survival after therapeutic dissection for palpable melanoma metastases. Ann. Surg. Oncol. 6: 139, 1999.
71. Buzaid, A. C., Tinoco, L. A., Jendiroba, D., et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J. Clin. Oncol. 13: 2361, 1995.
72. Reintgen, D. Melanoma nodal metastases. Surg. Oncol. Clin. North Am. 5: 105, 1996.
73. Morton, D. L., Wanek, L., Nizze, J. A., Elashoff, R. M., and Wong, J. H. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann. Surg. 214: 491, 1991.
74. Reintgen, D., Cruse, C. W., Wells, K. E., et al. The orderly progression of melanoma nodal metastases. Ann. Surg. 220: 759, 1994.
75. Morton, D. L., Wen, D.-R., Wong, J. H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127: 392, 1992.
76. Javaheri, S., Cruse, C. W., Stadelmann, W. K., and Reintgen, D. S. Sentinel node excision for the diagnosis of metastatic neuroendocrine carcinoma of the skin: A case report. Ann. Plast. Surg. 39: 299, 1997.
77. Messina, J. L., Reintgen, D. S., Cruse, C. W., et al. Selective lymphadenectomy in patients with merkel cell (cutaneous neuroendocrine) carcinoma. Ann. Surg. Oncol. 4: 389, 1997.
78. Stadelmann, W. K., Javaheri, S., Cruse, C. W., and Reintgen, D. S. The use of sentinel lymphadenectomy in squamous cell carcinoma of the wrist: A case report. J. Hand Surg. (Am.) 22: 726, 1997.
79. Cohen, M., Gat, A., Haddad, R., et al. Single-injection gamma probe-guided sentinel lymph node detection in 40 melanomatous lymphadenectomies. Ann. Plast. Surg. 41: 397, 1998.
80. Morton, D. L., Wen, D. R., and Cochran, A. J. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy or "watch and wait". Surg. Oncol. Clin. North Am. 1: 247, 1992.
81. Ollila, D. W., Foshag, L. J., Essner, R., Stern, S. L., and Morton, D. L. Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma. Ann. Surg. Oncol. 6: 150, 1999.
82. Haddad, F. F., Stall, A., Messina, J., et al. The progression of melanoma nodal metastasis is dependent on tumor thickness of the primary lesion. Ann. Surg. Oncol. 6: 144, 1999.
83. McMasters, K. M., Reintgen, D. S., Edwards, M. J., Cerrito, P., Krag, D. N., and Ross, M. I. Sunbelt melanoma trial (SMT): A multicenter trial of adjuvant interferon alfa-2b for melanoma patients with early lymph node metastasis detected by lymphatic mapping and sentinel lymph node biopsy. In Sunbelt Melanoma Trial Operations Manual University of Louisville Division of Surgical Oncology, 1996. www.sunbeltmelanoma.com.
84. Kapteijn, B. A., Nieweg, O. E., Valdes Olmos, R. A., et al. Reproducibility of lymphoscintigraphy for lymphatic mapping in cutaneous melanoma. J. Nucl. Med. 37: 972, 1996.
85. O'Brien, C. J., Uren, R. F., Thompson, J. F., et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am. J. Surg. 170: 461, 1995.
86. Reintgen, D. S., Rapaport, D. P., Tanabe, K. K., and Ross, M. Lymphatic Mapping and Sentinel Lymphadenectomy. In C. M. Balch (Ed.), Cutaneous Oncology, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 227-244.
87. Slingluff, C. L., Jr., Vollmer, R., Reintgen, D. S., and Seigler, H. F. Lethal thin malignant melanoma. Ann. Surg. 208: 150, 1988.
88. Slingluff, C. L., Jr., Stidham, K. R., Ricci, W. M., Stanley, W. E., and Seigler, H. F. Surgical management of regional lymph nodes in patients with melanoma: Experience with 4682 patients. Ann. Surg. 219: 120, 1994.
89. Gershenwald, J. E., Tseng, C.-H., Thompson, W., et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124: 203, 1998.
90. Messina, J. L., and Glass, L. F. Pathologic examination of the sentinel lymph node. J. Fla. Med. Assoc. 84: 153, 1997.
91. Barnhill, R. L., and Mihm, M. C. Histopathology and Precursor Lesions. In C. M. Balch (Ed.), Cutaneous Oncology, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 103-134.
92. Wang, X., Heller, R., Van Voorhis, N., et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann. Surg. 220: 768, 1994.
93. Berger, D. H., Feig, B. W., Podoloff, D., et al. Lymphoscintigraphy as a predictor of lymphatic drainage for cutaneous melanoma. Ann. Surg. Oncol. 4: 247, 1997.
94. Thompson, J. F., Niewind, P., Uren, R. F., et al. Single-dose isotope injection for both pre-operative lymphoscintigraphy and intraoperative sentinel lymph node identification in melanoma patients. Melanoma Res. 7: 500, 1997.
95. Rapaport, D. P., Stadelmann, W. K., Cruse, C. W., Wells, K. E., Albertini, J., and Reintgen, D. Identification of the Sentinel Lymph Node in Melanoma Patients Using Radiolymphoscintigraphy and Vital Blue Dye Injection. Presented at the Annual Meeting of the American Society of Plastic and Reconstructive Surgeons, Montreal, Canada, October 7, 1995.
96. Wells, K. E., Stadelmann, W. K., Rapaport, D. P., Hamlin, R., Cruse, C. W., and Reintgen, D. Parotid selective lymphadenectomy in malignant melanoma. Ann. Plast. Surg. 43: 1, 1999.
97. Krag, D. N., Meijer, S. J., Weaver, D., et al. Minimal-access surgery for staging of malignant melanoma. Arch. Surg. 130: 654, 1995.
98. Morton, D. L., and Bostick, P. J. Will the true sentinel node please stand? Ann. Surg. Oncol. 6: 12, 1999.
99. Albertini, J. J., Cruse, C. W., Rapaport, D. P., et al. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann. Surg. 223: 217, 1996.
100. Nathanson, S. D., Nelson, L., and Karvelis, K. C. Rates of flow of technetium 99m-labeled human serum albumin from peripheral injection sites to sentinel lymph nodes. Ann. Surg. Oncol. 3: 329, 1996.
101. O'Brien, C. J., Petersen-Schaefer, K., Papadopoulos, T., and Malka, V. Evaluation of 107 therapeutic and elective parotidectomies for cutaneous melanoma. Am. J. Surg. 168: 400, 1994.
102. McKean, M. E., Lee, K., and McGregor, I. A. The distribution of lymph nodes in and around the parotid gland: An anatomical study. Br. J. Surg. 38: 1, 1985.
103. Handley, W. S. The pathology of melanotic growths in relation to their treatment. Lancet 1: 996, 1907.
104. Batch, C. M., Urist, M. M., Karakousis, C. P., et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Ann. Surg. 218: 262, 1993.
105. Evans, G. R. D., and Manson, P. N. A variation in the appearance of melanoma-in-situ (Clark's level I malignant melanoma). Plast. Reconstr. Surg. 94: 513, 1994.
106. Karakousis, C. P., Balch, C., Urist, M., Ross, M., Smith, T., and Bartalucci, A. Local Recurrence in Malignant Melanoma: Long Term Results of a Surgical Trial (Abstract). Presented at the 48th Annual Cancer Symposium of the Society of Surgical Oncology, 1995.
107. Veronesi, U., and Cascinelli, N. Narrow excision (1-cm margin): A safe procedure for thin cutaneous melanoma. Arch. Surg. 126: 438, 1991.
108. Ross, M. I., and Balch, C. M. Surgical Treatment of Primary Melanoma. In C. M. Balch (Ed.), Cutaneous Oncology, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 141-154.
109. Kenady, D. E., Brown, B. W., and McBride, C. M. Excision of underlying fascia with a primary malignant melanoma: Effect on recurrence and survival rates. Surgery 92: 615, 1982.
110. Polk, H. C. Malignant melanoma: Current perspectives with emphasis upon treatment according to prognosis. J. Ky. Med. Assoc. 76: 12, 1978.
111. Lent, W. M., and Ariyan, S. Flap reconstruction following wide local excision for primary malignant melanoma of the head and neck region. Ann. Plast. Surg. 33: 23, 1994.
112. Byers, R. M., Smith, J. L., Russell, N., and Rosenberg, V. Malignant melanoma of the external ear. Am. J. Surg. 140: 518, 1980.
113. Cole, D. J., Mackay, G. J., Walker, B. F., Wooden, W. A., Murray, D. R., and Coleman, J. J. Melanoma of the external ear. J. Surg. Oncol. 50: 110, 1992.
114. Hudson, D. A., Krige, J. E., Strover, R. M., and King, H. S. Malignant melanoma of the external ear. Br. J. Plast. Surg. 43: 608, 1990.
115. Fisher, S. R. Cutaneous malignant melanoma of the head and neck. Laryngoscope 99: 822, 1989.
116. Fisher, S. R., Seigler, H. F., and George, S. L. Therapeutic and prognostic considerations of head and neck melanoma. Ann. Plast. Surg. 28: 78, 1992.
117. Wey, P. D., de la Cruz, C., Goydos, M. L., and Borah, G. L. Sentinel lymph node mapping in melanoma of the ear. Ann. Plast. Surg. 40: 506, 1998.
118. Cohen, L. M., and Zax, R. H. Recurrent lentigo maligna melanoma invading a skin graft successfully treated with mohs micrographic surgery. Cutis 57: 175, 1996.
119. Snow, S. N., Mohs, F. E., Oriba, H. A., Dudley, C. M., Leverson, G., and Hetzer, M. Cutaneous malignant melanoma treated by Mohs surgery. Dermatol. Surg. 23: 1055, 1997.
120. Bezwoda, W. R. The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Cancer Treat. Rev. 23: 17, 1997.
121. Nathan, F. E., and Mastrangelo, M. J. Systemic therapy in melanoma. Semin. Surg. Oncol. 14: 319, 1998.
122. Reintgen, D. S., Balch, C. M., Kirkwood, J., and Ross, M. Recent advances in the care of the patient with malignant melanoma. Ann. Surg. 225: 1, 1997.
123. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon-alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14: 7, 1996.
124. Reintgen, D. S., and Kirkwood, J. The adjuvant treatment of malignant melanoma. J. Fla. Med. Assoc. 84: 147, 1997.
125. Kirkwood, J. M., Ibrahim, J., Sondak, V., et al. Role of high-dose IFN in high-risk melanoma: Preliminary results of the E1690/S9111/C9190 US intergroup post-operative adjuvant trial of high and low-dose IFN alfa-2b (HDI and LDI) in resected high-risk primary or regional lymph node metastatic melanoma in relation to 10-year updated results of E1684. Eastern Cooperative Oncology Group Web site. Available at: http:// ecog.dfci.harvard.edu/~ecogdba/general/el690 abstract.html. Accessed March 15, 1999.
126. Bowsher, W. G., Taylor, B. A., and Hughes, L. E. Morbidity, mortality, and local recurrence following regional node dissection for melanoma. Br. J. Surg. 73: 906, 1986.
127. Ang, K. K., Byers, R. M., Peters, L. J., et al. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Arch. Otolaryngol. Head Neck Surg. 116: 169, 1990.
128. Trotti, A., and Peters, L. J. The role of radiotherapy in the primary management of cutaneous melanoma. Ann. Plast. Surg. 28: 39, 1992.
129. Karakouisis, C. P., Bartolucci, A. A., and Balch, C. M. Local Recurrence and Its Management. In C. M. Balch (Ed.), Cutaneous Oncology, 3rd Ed. St. Louis: Quality Medical Publishing, 1998. Pp. 155-162.
130. Weiss, M., Loprinzi, C. L., Creagan, E. T., Dalton, R. J., Novotny, P., and O'Fallon, J. R. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. J.A.M.A. 274: 1703, 1995.
131. Jillela, A., Mani, S., Nair, B., et al. The role of close follow-up of melanoma patients with AJCC stages I-III: A preliminary analysis. Proc. ASCO 14: 413, 1995.
132. Shumate, C. R., Urist, M. M., and Maddox, W. A. Melanoma recurrence surveillance: Patient or physician based? Ann. Surg. 221: 566, 1995.